|Bid||52.50 x 1000|
|Ask||53.53 x 2200|
|Day's Range||52.30 - 53.32|
|52 Week Range||46.94 - 70.05|
|Beta (3Y Monthly)||1.37|
|PE Ratio (TTM)||233.73|
|Forward Dividend & Yield||1.60 (3.03%)|
|1y Target Est||N/A|
NEW YORK, NY / ACCESSWIRE / November 13, 2018 / U.S. stocks closed down on Monday as oil prices continued to slide, raising concerns amongst investors. The Dow Jones Industrial Average plunged 2.32 percent ...
According to Willie Delwiche, investment strategist at R.W. Baird, “Oil being down could be a sign that the global economy is in a tough spot.” “The initial reaction to lower oil prices has been that they’ll be a boon for the middle class,” Delwiche said that the view could be inaccurate considering that consumer confidence doesn’t have more chances to grow, and because a smaller part of the American consumer’s budget goes to gasoline than it has in the previous years. The stock recorded a trading volume of 1,456,948 shares, which was above its three months average volume of 998,535 shares. On Friday, shares of Bristol-Myers Squibb recorded a trading volume of 8,107,392 shares, which was above the three months average volume of 7,213,656 shares.
NEW YORK, NY / ACCESSWIRE / November 9, 2018 / U.S. stocks retreated on Thursday after the Fed left interest rates unchanged and signaled that it would continue to tighten monetary policy at a gradual pace. Charlie Ripley, senior investment strategist at Allianz Investment Management said that, “With no press conference or expectation for policy change, most market participants viewed the November FOMC meeting as more of a non-event. “With only minimal changes to the statement the Fed is remaining vague about policy changes going forward and likely giving the committee more optionality in a changing market environment,” he added.
Bristol-Myers Squibb Company will take part in the Credit Suisse Annual Health Care Conference on Wednesday, November 14, 2018 in Scottsdale, AZ. Chris Boerner, chief commercial officer, will answer questions about the company at 8 a.m.
#FDA approves $BMY therapy for certain previously treated patients with #MultipleMyeloma.
-- Plans to Initiate MARIO-275, a Randomized, Global Phase 2 Study in 1H'19 -- NEW YORK and CAMBRIDGE, Mass. , Nov. 5, 2018 /PRNewswire/ -- Bristol-Myers Squibb Company (NYSE: BMY) and Infinity Pharmaceuticals, ...
-- Plans to Initiate MARIO-275, a Randomized, Global Phase 2 Study in 1H’19--
SAN DIEGO, Oct. 25, 2018 /PRNewswire/ -- Halozyme Therapeutics, Inc. (HALO) today announced that Bristol-Myers Squibb (BMY) has dosed the first subject in a clinical trial evaluating the safety, pharmacokinetics and pharmacodynamics of BMS-986179, an investigational anti-CD-73 antibody, using Halozyme's proprietary ENHANZE® drug delivery technology. "Since the signing of our collaboration with Bristol-Myers Squibb in September 2017, we have formed multiple joint program teams and have made rapid progress to begin assessment of ENHANZE with Bristol-Myers Squibb's extensive immuno-oncology portfolio," said Dr. Helen Torley, president and chief executive officer of Halozyme. "In addition to their initial selection of the PD-1 targeted asset, Bristol-Myers Squibb has chosen to evaluate BMS-986179 in combination with ENHANZE in certain cancers.
NEW YORK-- -- Increases Third Quarter Revenues 8% to $5.7 Billion Posts Third Quarter GAAP EPS of $1.16 and Non-GAAP EPS of $1.09 Presents Important New Clinical Data on Novel, Oral, Selective TYK2 Inhibitor for Potential Treatment of Patients with Moderate to Severe Plaque Psoriasis Additional Opdivo Approvals Including for Adjuvant Treatment of Adult Patients with Melanoma in the European Union Updates ...
Bristol-Myers Squibb Company today announced the results of a new analysis from the Phase 3 CheckMate -214 study, demonstrating that therapy with Opdivo plus Yervoy in patients with previously untreated advanced or metastatic renal cell carcinoma was associated with significantly longer treatment-free survival .
More than half of patients treated with Opdivo plus Yervoy survived to four years, with median overall survival not yet reached
Combination showed 60% objective response rate
Bristol-Myers Squibb Company today announced follow-up data evaluating Opdivo monotherapy and Opdivo in combination with Yervoy in patients with platinum-pretreated metastatic urothelial carcinoma .
New analysis submitted to U.S. Food and Drug Administration constitutes a major amendment to the Company’s supplemental Biologics License Application
NEW YORK, NY / ACCESSWIRE / October 19, 2018 / U.S. equities plunged on Thursday as worries over global growth weighed on the broader market and investors continued to digest the minutes from the Federal ...
- Growing body of evidence, including real-world studies, points to the clinical significance of anti-citrullinated protein antibody as a biomarker of poor prognosis in pati
Bristol-Myers Squibb Company today announced topline results from the Phase 3 CheckMate -331 study evaluating Opdivo versus the current standard of care, topotecan or amrubicin , in patients with small cell lung cancer who relapsed following platinum-based chemotherapy.
NEW YORK and HOLON, Israel , Oct. 11, 2018 /PRNewswire/ -- Bristol-Myers Squibb Company (NYSE: BMY) and Compugen (NASDAQ: CGEN) today announced the companies have entered into a clinical trial collaboration ...
Bristol-Myers Squibb Company and Compugen today announced the companies have entered into a clinical trial collaboration to evaluate the safety and tolerability of Compugen’s COM701, an investigational anti-PVRIG antibody, in combination with Bristol-Myers Squibb’s programmed death-1 immune checkpoint inhibitor Opdivo , in patients with advanced solid tumors.
Bristol-Myers Squibb Company today announced that the European Medicines Agency has validated the Company’s type II variation application for Empliciti in combination with pomalidomide and low-dose dexamethasone for the treatment of adult patients with multiple myeloma who have received at least two prior therapies, including lenalidomide and a proteasome inhibitor , and have demonstrated disease progression ...
The Board of Directors of Bristol-Myers Squibb Company today declared a quarterly dividend of forty cents per share on the $.10 par value Common Stock of the corporation.
Efficacy endpoints including ≥75% and 90% reduction in the Psoriasis Area and Severity Index were achieved following 12 weeks of treatment with ≥3 mg daily of BM
Bristol-Myers Squibb Company (BMY) will take part in the Morgan Stanley 2018 Global Health Care Conference on Thursday, September 13, 2018, in New York. Giovanni Caforio, M.D., chairman and chief executive officer will make formal remarks about the company and answer questions at 11:10 a.m. EDT. Investors and the general public are invited to listen to a live webcast of the session at http://investor.bms.com.
Bristol-Myers Squibb Company will announce results for the third quarter of 2018 on Thursday, October 25, 2018. During a conference call at 10:30 a.m. EDT on October 25, company executives will review financial information and will address inquiries from investors and analysts.
Today, for the fifth year in a row, Bristol-Myers Squibb Company (BMY) is launching Coast 2 Coast 4 Cancer, a nearly month-long cross-country bike ride to raise money for cancer research. From September 5-25, 109 company employees will ride a total of nearly 3,000 miles from Cannon Beach, OR, to Long Branch, NJ with the goal of raising $1 million for the V Foundation for Cancer Research. Funds raised will be matched dollar for dollar by Bristol-Myers Squibb Company, up to a $500,000 maximum donation.